局部晚期-话题@MedSci

#局部晚期#

176篇内容 | 3327人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1650826, encodeId=c5d01650826af, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=Clin Cancer Res：OX40激动剂Ivuxolimab在局部晚期或转移性癌症患者中的应用, objectType=article, longId=220548, objectId=8b2c22054893, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b2c22054893, replyNumber=0, likeNumber=59, createdTime=2022-01-05, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b2c22054893, moduleTitle=Clin Cancer Res：OX40激动剂Ivuxolimab在局部晚期或转移性癌症患者中的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b2c22054893)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650824, encodeId=e80c16508248c, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=Rhizen Pharmaceuticals AG宣布在Tenalisib (RP6530)治疗局部晚期或转移性乳腺癌的II期研究中首次向患者给药, objectType=article, longId=218658, objectId=c75f218658a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c75f218658a9, replyNumber=0, likeNumber=105, createdTime=2022-06-18, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c75f218658a9, moduleTitle=Rhizen Pharmaceuticals AG宣布在Tenalisib (RP6530)治疗局部晚期或转移性乳腺癌的II期研究中首次向患者给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c75f218658a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650806, encodeId=c6c7165080613, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=J Clin Oncol：新辅助DOS化疗可在标准疗法基础上进一步改善可切除局部晚期胃癌患者预后, objectType=article, longId=212904, objectId=f025212904a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f025212904a5, replyNumber=0, likeNumber=64, createdTime=2022-04-11, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f025212904a5, moduleTitle=J Clin Oncol：新辅助DOS化疗可在标准疗法基础上进一步改善可切除局部晚期胃癌患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f025212904a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650821, encodeId=557b165082116, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=16张精美图片：局部晚期非小细胞肺癌放疗靶区勾画, objectType=article, longId=218469, objectId=dbaf21846903, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbaf21846903, replyNumber=0, likeNumber=87, createdTime=2021-11-10, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbaf21846903, moduleTitle=16张精美图片：局部晚期非小细胞肺癌放疗靶区勾画, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dbaf21846903)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650814, encodeId=0f04165081445, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=Nat Cancer：新辅助治疗药物卡博替尼和纳武单抗治疗局部晚期肝细胞癌, objectType=article, longId=215171, objectId=df392151e1d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df392151e1d8, replyNumber=0, likeNumber=58, createdTime=2022-06-29, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df392151e1d8, moduleTitle=Nat Cancer：新辅助治疗药物卡博替尼和纳武单抗治疗局部晚期肝细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df392151e1d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650792, encodeId=61891650e924d, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=JCO：恩曲替尼治疗局部晚期或转移性ROS1融合阳性NSCLC总体安全有效，颅内ORR可达79.2%, objectType=article, longId=207818, objectId=f15320e81875, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f15320e81875, replyNumber=0, likeNumber=69, createdTime=2021-11-28, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f15320e81875, moduleTitle=JCO：恩曲替尼治疗局部晚期或转移性ROS1融合阳性NSCLC总体安全有效，颅内ORR可达79.2%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f15320e81875)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650783, encodeId=87591650e8351, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=Nat Commun：Ⅱ期随机临床试验: 局部晚期胃癌患者新辅助FLOT与SOX疗法较量, objectType=article, longId=203999, objectId=4c6120399925, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4c6120399925, replyNumber=0, likeNumber=69, createdTime=2021-05-13, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4c6120399925, moduleTitle=Nat Commun：Ⅱ期随机临床试验: 局部晚期胃癌患者新辅助FLOT与SOX疗法较量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4c6120399925)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650794, encodeId=c37d1650e94c4, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=Eur Urol：高风险局部和局部晚期肾细胞癌手术切除后的疾病复发、早期进展和总生存率预测 , objectType=article, longId=208759, objectId=4547208e591f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4547208e591f, replyNumber=0, likeNumber=75, createdTime=2021-05-19, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4547208e591f, moduleTitle=Eur Urol：高风险局部和局部晚期肾细胞癌手术切除后的疾病复发、早期进展和总生存率预测 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4547208e591f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650810, encodeId=ef9816508101c, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=Ann Oncol: atezolizumab联合白蛋白结合型紫杉醇一线治疗不可切除、局部晚期或转移性三阴性乳腺癌的疗效: IMpassion130最终总生存分析, objectType=article, longId=213736, objectId=41a6213e36ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41a6213e36ec, replyNumber=0, likeNumber=93, createdTime=2022-06-15, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41a6213e36ec, moduleTitle=Ann Oncol: atezolizumab联合白蛋白结合型紫杉醇一线治疗不可切除、局部晚期或转移性三阴性乳腺癌的疗效: IMpassion130最终总生存分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41a6213e36ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650799, encodeId=064e1650e9902, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=Cancer：HIV-1蛋白酶抑制剂奈非那韦联合标准放化疗治疗局部晚期宫颈癌的效果, objectType=article, longId=210992, objectId=3d082109924e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d082109924e, replyNumber=0, likeNumber=58, createdTime=2022-01-08, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d082109924e, moduleTitle=Cancer：HIV-1蛋白酶抑制剂奈非那韦联合标准放化疗治疗局部晚期宫颈癌的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d082109924e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650787, encodeId=1c8c1650e8795, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=J Clin Oncol：全盆腔预防性放疗较单纯前列腺放疗可进一步改善局部晚期前列腺癌患者预后, objectType=article, longId=206566, objectId=c971206566db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c971206566db, replyNumber=0, likeNumber=66, createdTime=2021-04-10, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c971206566db, moduleTitle=J Clin Oncol：全盆腔预防性放疗较单纯前列腺放疗可进一步改善局部晚期前列腺癌患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c971206566db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650793, encodeId=32671650e9322, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=JAMA Surg：局部晚期食管癌食管切除术前是新辅助放化疗还是新辅助化疗？, objectType=article, longId=208704, objectId=b07d208e046f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b07d208e046f, replyNumber=0, likeNumber=60, createdTime=2021-07-10, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b07d208e046f, moduleTitle=JAMA Surg：局部晚期食管癌食管切除术前是新辅助放化疗还是新辅助化疗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b07d208e046f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650801, encodeId=3df21650801fa, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=JEADV：Hh通路抑制剂Vismodegib在临床实践中治疗局部晚期基底细胞癌的有效性, objectType=article, longId=211026, objectId=234e21102685, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=234e21102685, replyNumber=0, likeNumber=70, createdTime=2021-09-17, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=234e21102685, moduleTitle=JEADV：Hh通路抑制剂Vismodegib在临床实践中治疗局部晚期基底细胞癌的有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=234e21102685)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650780, encodeId=e7ba1650e80b2, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=Br J Cancer：尼妥珠单抗联合顺铂放疗改善高HIF1α表达的局部晚期头颈部鳞癌患者的预后, objectType=article, longId=201080, objectId=d88e20108084, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d88e20108084, replyNumber=0, likeNumber=91, createdTime=2020-09-25, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d88e20108084, moduleTitle=Br J Cancer：尼妥珠单抗联合顺铂放疗改善高HIF1α表达的局部晚期头颈部鳞癌患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d88e20108084)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650812, encodeId=a16e1650812f6, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=J Clin Oncol：CMB305联合阿特珠单抗治疗局部晚期滑膜肉瘤或粘液样脂肪肉瘤患者的疗效和安全性, objectType=article, longId=214523, objectId=8b672145231c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b672145231c, replyNumber=0, likeNumber=70, createdTime=2021-12-05, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b672145231c, moduleTitle=J Clin Oncol：CMB305联合阿特珠单抗治疗局部晚期滑膜肉瘤或粘液样脂肪肉瘤患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b672145231c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650784, encodeId=d3c61650e84e8, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=Lancet oncol：3期| 术前短疗程放疗+化疗可改善局部晚期直肠癌患者预后, objectType=article, longId=204379, objectId=ba042043e9ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba042043e9ce, replyNumber=0, likeNumber=80, createdTime=2021-03-23, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba042043e9ce, moduleTitle=Lancet oncol：3期| 术前短疗程放疗+化疗可改善局部晚期直肠癌患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba042043e9ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650808, encodeId=90fb1650808c1, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=JAMA Surg：新辅助放化疗联合手术可显著改善中国局部晚期食管鳞癌患者的长期预后, objectType=article, longId=213435, objectId=f68521343500, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f68521343500, replyNumber=0, likeNumber=85, createdTime=2022-04-27, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f68521343500, moduleTitle=JAMA Surg：新辅助放化疗联合手术可显著改善中国局部晚期食管鳞癌患者的长期预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f68521343500)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650797, encodeId=965b1650e9717, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=Lancet oncol：多种放化疗联合方案治疗局部晚期头颈癌的疗效对比, objectType=article, longId=210448, objectId=c74521044816, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c74521044816, replyNumber=0, likeNumber=59, createdTime=2021-08-27, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c74521044816, moduleTitle=Lancet oncol：多种放化疗联合方案治疗局部晚期头颈癌的疗效对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c74521044816)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650800, encodeId=65fc16508001d, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=Eur Urol：铂治疗的局部晚期或转移性尿路上皮癌患者的Atezolizumab与化疗治疗比较 , objectType=article, longId=211015, objectId=27af21101554, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27af21101554, replyNumber=0, likeNumber=61, createdTime=2022-03-12, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27af21101554, moduleTitle=Eur Urol：铂治疗的局部晚期或转移性尿路上皮癌患者的Atezolizumab与化疗治疗比较 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=27af21101554)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650791, encodeId=209a1650e917b, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=NICE：建议将Kisqali（ribociclib）与氟维司群联用，用于治疗局部晚期或转移性乳腺癌, objectType=article, longId=207679, objectId=6d4b20e679c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d4b20e679c7, replyNumber=0, likeNumber=74, createdTime=2021-10-31, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d4b20e679c7, moduleTitle=NICE：建议将Kisqali（ribociclib）与氟维司群联用，用于治疗局部晚期或转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d4b20e679c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

局部晚期

2020-05-29

一叶知秋 (审核中...)

前往app查看评论内容

#局部晚期#

Clin Cancer Res：OX40激动剂Ivuxolimab在局部晚期或转移性癌症患者中的应用

2022-01-05

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

Rhizen Pharmaceuticals AG宣布在Tenalisib (RP6530)治疗局部晚期或转移性乳腺癌的II期研究中首次向患者给药

2022-06-18

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

J Clin Oncol：新辅助DOS化疗可在标准疗法基础上进一步改善可切除局部晚期胃癌患者预后

2022-04-11

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

16张精美图片：局部晚期非小细胞肺癌放疗靶区勾画

2021-11-10

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

Nat Cancer：新辅助治疗药物卡博替尼和纳武单抗治疗局部晚期肝细胞癌

2022-06-29

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

JCO：恩曲替尼治疗局部晚期或转移性ROS1融合阳性NSCLC总体安全有效，颅内ORR可达79.2%

2021-11-28

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

Nat Commun：Ⅱ期随机临床试验: 局部晚期胃癌患者新辅助FLOT与SOX疗法较量

2021-05-13

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

Eur Urol：高风险局部和局部晚期肾细胞癌手术切除后的疾病复发、早期进展和总生存率预测

2021-05-19

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

Ann Oncol: atezolizumab联合白蛋白结合型紫杉醇一线治疗不可切除、局部晚期或转移性三阴性乳腺癌的疗效: IMpassion130最终总生存分析

2022-06-15

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

Cancer：HIV-1蛋白酶抑制剂奈非那韦联合标准放化疗治疗局部晚期宫颈癌的效果

2022-01-08

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

J Clin Oncol：全盆腔预防性放疗较单纯前列腺放疗可进一步改善局部晚期前列腺癌患者预后

2021-04-10

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

JAMA Surg：局部晚期食管癌食管切除术前是新辅助放化疗还是新辅助化疗？

2021-07-10

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

JEADV：Hh通路抑制剂Vismodegib在临床实践中治疗局部晚期基底细胞癌的有效性

2021-09-17

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

Br J Cancer：尼妥珠单抗联合顺铂放疗改善高HIF1α表达的局部晚期头颈部鳞癌患者的预后

2020-09-25

仁心济世 (审核中...)

前往app查看评论内容

#局部晚期#

J Clin Oncol：CMB305联合阿特珠单抗治疗局部晚期滑膜肉瘤或粘液样脂肪肉瘤患者的疗效和安全性

2021-12-05

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

Lancet oncol：3期| 术前短疗程放疗+化疗可改善局部晚期直肠癌患者预后

2021-03-23

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

JAMA Surg：新辅助放化疗联合手术可显著改善中国局部晚期食管鳞癌患者的长期预后

2022-04-27

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

Lancet oncol：多种放化疗联合方案治疗局部晚期头颈癌的疗效对比

2021-08-27

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

Eur Urol：铂治疗的局部晚期或转移性尿路上皮癌患者的Atezolizumab与化疗治疗比较

2022-03-12

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

NICE：建议将Kisqali（ribociclib）与氟维司群联用，用于治疗局部晚期或转移性乳腺癌

2021-10-31

科室
- - 订阅+
  - 更多科室
工具
服务